Regeneron Pharmaceuticals, Inc. last reported quarterly results on Oct 6, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $5.1 billion (+36.3% year over year) and diluted EPS of $18.45. It usually reports 6–12 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 6–12 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 6, 2026
6 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
5,116
+36.3%
|
1,949
+33.5%
|
18.45
+35.5%
|
|
Jul 6, 2026
6 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
4,291
+16.7%
|
1,297
-6.8%
|
12.23
-4.5%
|
|
Apr 8, 2026
8 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
3,605
+19.0%
|
727
-10.1%
|
6.75
-7.2%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
3,884
+2.5%
|
845
-8.0%
|
7.84
-2.9%
|
|
Oct 6, 2025
6 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3,754
+0.9%
|
1,460
+8.9%
|
13.62
+18.0%
|
|
Aug 1, 2025
32 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3,676
+3.6%
|
1,392
-2.8%
|
12.81
+3.2%
|
|
Apr 29, 2025
29 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3,029
-3.7%
|
809
+12.0%
|
7.27
+15.9%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
3,789
+10.3%
|
918
-20.9%
|
8.08
-20.8%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Tarrytown, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 872589
- Former names
- REGENERON PHARMACEUTICALS INC (until Jun 19, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.